GnRH antagonist versus follicular-phase single-dose GnRH agonist protocol in patients of normal ovarian responses during controlled ovarian stimulation

References

• Williams SC, Gibbons WE, Muasher SJ, et al. Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist. Fertil Steril. 2002;78:1068–1072.
   PubMed Web of Science ®Google Scholar
• Shrestha D, La X, Feng HL. Comparison of different stimulation protocols used in in vitro fertilization: a review. Ann Transl Med. 2015;3:137.
   PubMed Web of Science ®Google Scholar
• Albuquerque LE, Tso LO, Saconato H, et al. Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database Sys Rev. 2013;CD002808.
   PubMed Web of Science ®Google Scholar
• Hsieh YY, Chang CC, Tsai HD. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. Taiwan J Obst Gynecol. 2008;47:66–74.
   PubMed Web of Science ®Google Scholar
• Kondaveeti-Gordon U, Harrison RF, Barry-Kinsella C, et al. A randomized prospective study of early follicular or midluteal initiation of long protocol gonadotropin-releasing hormone in an in vitro fertilization program. Fertil Steril. 1996;66:582–586.
   PubMed Web of Science ®Google Scholar
• Pellicer A, Simon C, Miro F, et al. Ovarian response and outcome of in-vitro fertilization in patients treated with gonadotrophin-releasing hormone analogues in different phases of the menstrual cycle. Hum Reprod. 1989;4:285–289.
   PubMedGoogle Scholar
• Ron-El R, Herman A, Golan A, et al. The comparison of early follicular and midluteal administration of long-acting gonadotropin-releasing hormone agonist. Fertil Steril. 1990;54:233–237.
   PubMed Web of Science ®Google Scholar
• Orvieto R, Meltzer S, Rabinson J, et al. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity. Fertil Steril. 2008;90:1294–1296.
   PubMed Web of Science ®Google Scholar
• Tarlatzis BC, Fauser BC, Kolibianakis EM, et al. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update. 2006;12:333–340.
   PubMed Web of Science ®Google Scholar
• Engmann L, Benadiva C, Humaidan P. GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis. Reproduct Biomed Online. 2016;32:274–285.
   PubMed Web of Science ®Google Scholar
• Nasiri N, Eftekhari-Yazdi P. An overview of the available methods for morphological scoring of pre-implantation embryos in in vitro fertilization. Cell J. 2015;16:392–405.
   PubMed Web of Science ®Google Scholar
• Barnhart K, Dunsmoor-Su R, Coutifaris C. Effect of endometriosis on in vitro fertilization. Fertil Steril. 2002;77:1148–1155.
   PubMed Web of Science ®Google Scholar
• Surrey ES, Silverberg KM, Surrey MW, et al. Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis. Fertil Steril. 2002;78:699–704.
   PubMed Web of Science ®Google Scholar
• Ren J, Sha A, Han D, et al. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment? Fertil Steril. 2014;102:75–81.
   PubMed Web of Science ®Google Scholar
• Edwards RG. Clinical approaches to increasing uterine receptivity during human implantation. Human Reprod. 1995;10:60–66.
   PubMed Web of Science ®Google Scholar
• Oliveira JB, Baruffi R, Petersen CG, et al. Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis. Reprod Biol Endocrinol. 2010;8:107.
   PubMed Web of Science ®Google Scholar
• Blockeel C, Sterrenburg MD, Broekmans FJ, et al. Follicular phase endocrine characteristics during ovarian stimulation and GnRH antagonist cotreatment for IVF: RCT comparing recFSH initiated on cycle day 2 or 5. J Clin Endocrinol Metabol. 2011;96:1122–1128.
   PubMed Web of Science ®Google Scholar
• Ruan HC, Zhu XM, Luo Q, et al. Ovarian stimulation with GnRH agonist, but not GnRH antagonist, partially restores the expression of endometrial integrin beta3 and leukaemia-inhibitory factor and improves uterine receptivity in mice. Hum Reprod. 2006;21:2521–2529.
   PubMed Web of Science ®Google Scholar
• Esposito MA, Barnhart KT, Coutifaris C, et al. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone. Fertil Steril. 2001;75:519–524.
   PubMed Web of Science ®Google Scholar
• Al-Inany HG, Youssef MA, Ayeleke RO, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database System Rev. 2016;4:CD001750.
   PubMedGoogle Scholar
• Banga FR, Huirne JA, Korsen T, et al. Pituitary sensitizing effect of GnRH antagonists: a mechanism explaining LH escape during IVF? Human Reprod. 2010;25:1513–1519.
   PubMed Web of Science ®Google Scholar
• Meng Y, Guo Y, Qian Y, et al. Effects of GnRH antagonist on endometrial protein profiles in the window of implantation. Proteomics. 2014;14:2350–2359.
   PubMed Web of Science ®Google Scholar
• Park CW, Hwang YI, Koo HS, et al. Early gonadotropin-releasing hormone antagonist start improves follicular synchronization and pregnancy outcome as compared to the conventional antagonist protocol. Clin Exp Reprod Med. 2014;41:158–164.
   PubMedGoogle Scholar
• Loumaye E, Engrand P, Howles CM, et al. Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome. Fertil Steril. 1997;67:889–899.
   PubMed Web of Science ®Google Scholar
• Bu Z, Wang K, Guo Y, et al. Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and embryo transfer. Int J Clin Exp Med. 2015;8:11327–11331.
   PubMed Web of Science ®Google Scholar
• Sandoval JS, Steward RG, Chen C, et al. High peak estradiol/mature oocyte ratio predicts lower clinical pregnancy, ongoing pregnancy, and live birth rates in GnRH antagonist intracytoplasmic sperm injection cycles. J Reprod Med. 2016;61:11–16.
   PubMed Web of Science ®Google Scholar
• Var T, Tonguc E, Dogan M, et al. Relationship between the oestradiol/oocyte ratio and the outcome of assisted reproductive technology cycles with gonadotropin releasing hormone agonist. Gynecol Endocrinol: Off J Int Soc Gynecol Endocrinol. 2011;27:558–561.
   PubMed Web of Science ®Google Scholar
• Roque M, Valle M, Guimaraes F, et al. Freeze-all cycle for all normal responders? J Assist Reprod Genet. 2017;34:179–185.
   PubMed Web of Science ®Google Scholar
• Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online. 2007;14:640–649.
   PubMed Web of Science ®Google Scholar
• Prapas N, Tavaniotou A, Panagiotidis Y, et al. GnRH antagonists and endometrial receptivity in oocyte recipients: a prospective randomized trial. Reprod Biomed Online. 2009;18:276–281.
   PubMed Web of Science ®Google Scholar
• Xu B, Wang J, Xia L, et al. Increased uterine NK cell numbers and perforin expression during the implantation phase in IVF cycles with GnRH antagonist protocol. Sci Rep. 2017;7:39912.
   PubMed Web of Science ®Google Scholar
• Cota AM, Oliveira JB, Petersen CG, et al. GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology. Reprod Biol Endocrinol. 2012;10:33.
   PubMed Web of Science ®Google Scholar